No Data
No Data
AlloVir | 10-Q: Q3 2024 Earnings Report
AlloVir and Kalaris Enter Merger to Advance Retinal Disease Therapies
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Sector Update: Health Care Stocks Edge Higher Premarket Friday
Sector Update: Health Care
Express News | Allovir - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Kalaris Termination Fee of $3.5 Mln
No Data